Drugs Made In America Acquisition Corp.
DMAA
Analytical Summary
Drugs Made In America Acquisition Corp. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.
Bullish Indicators
- No bullish signals detected.
Bearish Risks
- Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ |
|---|---|---|
| Return on Invested Capital (%) |
30.6%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-1.2%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— |
| Return on Common Equity (%) (%) |
-81.8%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-782%)
|
— |
Secondary lens
Benchmark Lens
Compare DMAA against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare DMAA against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for DMAA
No bullish signals detected
Return on Common Equity (%) is in the bottom quartile
Percentile Rankings
How DMAA compares to all companies
Peer Comparison
DMAA vs similar peers
Compare DMAA with peers
Stack DMAA against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 2 years · 8 quarters